Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Patients with COVID-19 Receiving Invasive Mechanical Ventilation
Boehringer Ingelheim and Eli Lilly Present Results of Jardiance (empagliflozin) in P-III EMPEROR-Preserved Trial for HFpEF at ASN Kidney Week 2021
Shots:
- The P-III COV-BARRIER substudy evaluates baricitinib + SoC vs PBO + SoC in 101 adult patients with COVID-19 who are on mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
- The results showed reduction in mortality (46% & 44%) @ Day 28 & 60. The findings are consistent with the reduction in mortality in the overall COV-BARRIER patient population
- Lilly plans to publish the results in a peer-reviewed journal in the coming mos. & share the data with regulatory authorities in the US, EU & other geographies. Additionally, FDA has broadened the EUA for baricitinib to allow treatment with or without remdesivir on Jul 28, 2021
Click here to to read full press release/ article | Ref: PR Newswire | Image: Forbes